Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 331

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 331
---
 have been made available to the Purchaser.

| 42. | Fairness Opinion |

The Transaction Committee has received the Fairness Opinion. The Fairness Opinion has not been withdrawn or modified. The Company has been authorized by the Financial Advisor to include the Fairness Opinion in the Circular.

| 43. | Board and Transaction Committee Approval |

| (a) | The Transaction Committee, after consultation with its financial and legal advisors, has unanimously                                                                                                                                             
 recommended that the consideration to be received under the Arrangement is fair from a financial point of view to the Shareholders and that it would be in the best interests of the Company and the Shareholders for the Company to support and 
 facilitate the Arrangement, enter into this Agreement and to take all reasonable action to support the Arrangement and to recommend acceptance of the Arrangement to the Shareholders.                                                           |

| (b) | After consultation by the Board of Directors with its financial and legal advisors and the Transaction 
 Committee, the members of the Board of Directors who voted thereon have unanimously determined that:   |

| (i) | the Contemplated Transactions are in the best interests of the Company and the Shareholders and, accordingly,                                                                                                       
 has unanimously approved the entering into of this Agreement and the making of the Board Recommendation and no action has been taken to amend or supersede such determinations, resolutions, or authorizations; and |

| (ii) | the press release to be issued by the Purchaser announcing the Contemplated Transactions may so state and that 
 references to such support may be made in the Circular and other documents relating to the Arrangement.        |

A-85

SIGNING VERSION

SCHEDULE F

FORM OF CVR AGREEMENT

This CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [●] (this “Agreement”), is
entered into by and between Xeno Acquisition Corp. (the “Purchaser”), a Delaware corporation and a wholly owned Subsidiary of XenoTherapeutics Inc (the “Parent”), BROADRIDGE CORPORATE ISSUER SOLUTIONS, LLC, a Pennsylvania limited liability company, as Rights Agent (as defined herein), and [●], solely in its capacity as the initial representative, agent and attorney in-fact of the Holders
(the “Representative”).

RECITALS

WHEREAS, Parent, Purchaser and Repare Therapeutics Inc., a corporation incorporated under the Business Corporations Act (Québec),
organized and existing under the laws of Canada and having its